

31 March 2021

Intuitive Investments Group plc

Investment in CardiNor AS

Intuitive Investments Group plc (AIM: IIG) (“IIG” or the “Company”), a closed-end investment company focussed on the life sciences sector, announces an investment of £125,000 to acquire ordinary shares in CardiNor AS (“CardiNor”), representing a 1.8 per cent. interest in CardiNor’s enlarged share capital.

CardiNor is a Norwegian biotech company established in June 2015 to commercialise the development of secretoneurin (“SN”), an important new biomarker for cardiovascular disease (“CVD”). SN is the only biomarker shown to be associated with biological processes linked to cardiomyocyte handling. This unique biological function explains why SN presents as an independent and strong predictor of mortality in all major patient cohorts, including ventricular arrhythmia, acute heart failure, acute respiratory failure patients with CVD and severe sepsis. CardiNor has completed development of a research assay based on immunoassay technology to measure SN in blood and the assay is under further clinical development, including to obtain a CE mark. More information can be found at: <https://cardinor.com/>.

In the year ended 31 December 2020, per CardiNor’s unaudited management accounts, it achieved a loss after tax of approximately £141,000 and, as at 31 December 2020, had net assets of approximately £500,000, assuming an exchange rate of 11.87NOK/GBP.

For further information, please contact:

Intuitive Investments Group plc

David Evans, Executive Chairman
Robert Naylor, CEO

www.iigplc.com

Via Walbrook PR

Strand Hanson Limited - Nominated Adviser

James Harris / James Dance / James Bellman

+44 (0) 20 7409 3494

Turner Pope Investments (TPI) Ltd - Broker

Andrew Thacker / Zoe Alexander

+44 (0) 20 3657 0050

Walbrook PR Limited - Media & Investor Relations

Sam Allen / Paul McManus

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

+44 (0)7502 558 258 / +44 (0) 7980 541 893

About Intuitive Investments Group plc

The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board’s experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.